-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Is Mabpharm Limited (HKG:2181) Popular Amongst Insiders?
Is Mabpharm Limited (HKG:2181) Popular Amongst Insiders?
If you want to know who really controls Mabpharm Limited (HKG:2181), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.
Mabpharm is a smaller company with a market capitalization of HK$2.9b, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased shares. We can zoom in on the different ownership groups, to learn more about Mabpharm.
View our latest analysis for Mabpharm
SEHK:2181 Ownership Breakdown July 7th 2022What Does The Lack Of Institutional Ownership Tell Us About Mabpharm?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. Alternatively, there might be something about the company that has kept institutional investors away. Mabpharm's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely.
SEHK:2181 Earnings and Revenue Growth July 7th 2022We note that hedge funds don't have a meaningful investment in Mabpharm. Looking at our data, we can see that the largest shareholder is Jianjun Guo with 50% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 18% and 5.2%, of the shares outstanding, respectively.
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Mabpharm
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own a reasonable proportion of Mabpharm Limited. It has a market capitalization of just HK$2.9b, and insiders have HK$1.5b worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 23% stake in Mabpharm. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
Private equity firms hold a 23% stake in Mabpharm. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
Private Company Ownership
Our data indicates that Private Companies hold 4.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Mabpharm has 3 warning signs (and 2 which can't be ignored) we think you should know about.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了Mabpharm Limited(HKG:2181),那么你必须看看它的股票登记处的构成。内部人士通常持有大量较年轻、规模较小的公司,而大公司往往有机构作为股东。我非常希望看到至少有一点内部人持股。正如查理·芒格所说,给我看激励措施,我就会告诉你结果。
Mabpharm是一家规模较小的公司,市值为29亿港元,因此它可能仍在许多机构投资者的雷达下飞行。我们对公司所有权的分析显示,机构投资者尚未购买股票。我们可以放大不同的所有权组,了解更多关于Mabpharm的信息。
查看我们对Mabpharm的最新分析
联交所:2181拥有权分类2022年7月7日机构所有权的缺失告诉了我们关于Mabpharm的什么?
交易不太活跃的小公司往往缺乏机构投资者,但大公司没有机构投资者的情况较少。
为什么没有机构持有一家公司的股票,可能有各种原因。通常情况下,新上市的小型公司不会引起基金经理太多关注,因为大型基金管理公司不可能在该公司建立有意义的头寸。或者,该公司可能有某些方面让机构投资者望而却步。Mabpharm的盈利和营收记录(见下文)对机构投资者来说可能并不令人信服--或者他们可能只是没有密切关注这项业务。
联交所:2181盈利及收入增长2022年7月7日我们注意到,对冲基金没有对Mabpharm进行有意义的投资。看看我们的数据,我们可以看到,第一大股东是郭建军,持有50%的流通股。与此同时,第二大和第三大股东分别持有流通股的18%和5.2%。
在进一步挖掘后,我们发现,前两名股东共同控制着公司一半以上的股份,这意味着他们拥有相当大的权力来影响公司的决策。
虽然研究一家公司的机构持股可以增加你的研究价值,但研究分析师的建议以更深入地了解一只股票的预期表现也是一个很好的做法。我们的信息显示,分析师没有对该股进行任何报道,因此它可能鲜为人知。
Mabpharm的内部人士所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们的最新数据显示,内部人士持有Mabpharm Limited相当比例的股份。它的市值只有29亿港元,内部人士以自己的名义持有价值15亿港元的股票。我们会说,这表明了与股东的一致,但值得注意的是,该公司仍相当小;一些内部人士可能创建了这家企业。你可以点击这里,看看这些内部人士是一直在买入还是卖出。
一般公有制
公众通常是个人投资者,他们持有Mabpharm 23%的股份。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私募股权所有权
私募股权公司持有Mabpharm 23%的股份。这表明,他们可以在关键的政策决策中发挥影响力。一些投资者可能会因此而受到鼓舞,因为私人股本有时能够鼓励有助于市场看到公司价值的策略。或者,这些持有者可能会在投资上市后退出。
私营公司所有权
我们的数据显示,私营公司持有该公司4.0%的股份。或许有必要对此进行更深入的研究。如果关联方,如内部人士,对这些私营公司中的一家有利害关系,则应在年报中披露。私营公司也可能对该公司拥有战略利益。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。以风险为例-Mabpharm拥有3个警示标志(和2个不容忽视的问题)我们认为你应该知道。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费令人感兴趣的公司名单,有强劲的财务数据支持。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧